ERBB2 and breast carcinoma: Patients enrolled in TH3RESA [26] were adults with centrally confirmed HER2+ advanced breast cancer previously treated with anti-HER2 therapies (advanced setting) and a taxane (any setting) and with progression on two or more anti-HER2 therapies, including trastuzumab and lapatinib (advanced setting).